{"id":591368,"date":"2022-03-15T18:06:02","date_gmt":"2022-03-15T18:06:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=591368"},"modified":"2022-03-15T18:06:02","modified_gmt":"2022-03-15T18:06:02","slug":"paroxysmal-supraventricular-tachycardia-market-to-register-sustainable-growth-during-the-forecast-period-delveinsight-key-companies-3m-pharmaceuticals-milestone-therapeutics-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/paroxysmal-supraventricular-tachycardia-market-to-register-sustainable-growth-during-the-forecast-period-delveinsight-key-companies-3m-pharmaceuticals-milestone-therapeutics-and-others_591368.html","title":{"rendered":"Paroxysmal Supraventricular Tachycardia Market to Register Sustainable Growth During the Forecast Period – DelveInsight | Key Companies – 3M Pharmaceuticals, Milestone Therapeutics, and Others"},"content":{"rendered":"
\n
\"Paroxysmal<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Paroxysmal Supraventricular Tachycardia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Paroxysmal Supraventricular Tachycardia Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/div>\n

The Paroxysmal Supraventricular Tachycardia market<\/strong> report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

\"Paroxysmal<\/p>\n

Paroxysmal Supraventricular Tachycardia: An Overview<\/strong><\/p>\n

Paroxysmal supraventricular tachycardia (PSVT) is another type of “short-circuit” arrhythmia. It may result either from atrioventricular nodal re-entrant tachycardia (AVNRT) or from an accessory pathway, which may occur as part of the Wolff-Parkinson-White (WPW) syndrome. In AVNRT, a small extra pathway exists in or near the AV node. If an electrical impulse enters this pathway, it may start travelling in a circular pattern that causes the heart to abruptly start beating fast and regular.<\/em><\/p>\n

PSVT may occur at any age and commonly occurs in patients who have no other types of heart disease. Patients with PSVT typically describe a rapid, or racing, regular heartbeat (between 130 and 230 beats per minute) that starts and stops abruptly. It is commonly misdiagnosed as a panic attack. With the exception of some patients with the Wolff-Parkinson-White syndrome, PSVT generally is not a dangerous arrhythmia. However, it can result in debilitating symptoms. Treatment options include a variety of drugs or catheter ablation, which cures the problem in most patients.<\/em><\/p>\n

Paroxysmal Supraventricular Tachycardia Market Key Facts<\/strong><\/p>\n